Clostridium difficile infection: New insights into management

Sahil Khanna, Darrell S. Pardi

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

Clostridium difficile was first described as a cause of diarrhea in 1978 and is now among the leading 3 hospital-acquired infections in the United States, along with methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. In the past 2 decades, there has been an increase in the incidence, severity, and recurrence rates of C difficile infection, all of which are associated with poor outcomes. In addition, several novel risk factors and newer treatment methods are emerging, including fidaxomicin therapy, treatment using monoclonal antibodies, and fecal microbiota transplantation, that have shown promise for the treatment of C difficile infection. This review focuses on the changing epidemiology, risk factors, and newer methods for treatment of C difficile infection.

Original languageEnglish (US)
Pages (from-to)1106-1117
Number of pages12
JournalMayo Clinic Proceedings
Volume87
Issue number11
DOIs
StatePublished - 2012

Fingerprint

Clostridium Infections
Clostridium difficile
Infection
Therapeutics
Methicillin-Resistant Staphylococcus aureus
Cross Infection
Diarrhea
Epidemiology
Monoclonal Antibodies
Recurrence
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Clostridium difficile infection : New insights into management. / Khanna, Sahil; Pardi, Darrell S.

In: Mayo Clinic Proceedings, Vol. 87, No. 11, 2012, p. 1106-1117.

Research output: Contribution to journalArticle

Khanna, Sahil ; Pardi, Darrell S. / Clostridium difficile infection : New insights into management. In: Mayo Clinic Proceedings. 2012 ; Vol. 87, No. 11. pp. 1106-1117.
@article{3351556a23ce4d599ec59c1f97faf3af,
title = "Clostridium difficile infection: New insights into management",
abstract = "Clostridium difficile was first described as a cause of diarrhea in 1978 and is now among the leading 3 hospital-acquired infections in the United States, along with methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. In the past 2 decades, there has been an increase in the incidence, severity, and recurrence rates of C difficile infection, all of which are associated with poor outcomes. In addition, several novel risk factors and newer treatment methods are emerging, including fidaxomicin therapy, treatment using monoclonal antibodies, and fecal microbiota transplantation, that have shown promise for the treatment of C difficile infection. This review focuses on the changing epidemiology, risk factors, and newer methods for treatment of C difficile infection.",
author = "Sahil Khanna and Pardi, {Darrell S.}",
year = "2012",
doi = "10.1016/j.mayocp.2012.07.016",
language = "English (US)",
volume = "87",
pages = "1106--1117",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "11",

}

TY - JOUR

T1 - Clostridium difficile infection

T2 - New insights into management

AU - Khanna, Sahil

AU - Pardi, Darrell S.

PY - 2012

Y1 - 2012

N2 - Clostridium difficile was first described as a cause of diarrhea in 1978 and is now among the leading 3 hospital-acquired infections in the United States, along with methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. In the past 2 decades, there has been an increase in the incidence, severity, and recurrence rates of C difficile infection, all of which are associated with poor outcomes. In addition, several novel risk factors and newer treatment methods are emerging, including fidaxomicin therapy, treatment using monoclonal antibodies, and fecal microbiota transplantation, that have shown promise for the treatment of C difficile infection. This review focuses on the changing epidemiology, risk factors, and newer methods for treatment of C difficile infection.

AB - Clostridium difficile was first described as a cause of diarrhea in 1978 and is now among the leading 3 hospital-acquired infections in the United States, along with methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. In the past 2 decades, there has been an increase in the incidence, severity, and recurrence rates of C difficile infection, all of which are associated with poor outcomes. In addition, several novel risk factors and newer treatment methods are emerging, including fidaxomicin therapy, treatment using monoclonal antibodies, and fecal microbiota transplantation, that have shown promise for the treatment of C difficile infection. This review focuses on the changing epidemiology, risk factors, and newer methods for treatment of C difficile infection.

UR - http://www.scopus.com/inward/record.url?scp=84872236149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872236149&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2012.07.016

DO - 10.1016/j.mayocp.2012.07.016

M3 - Article

C2 - 23127735

AN - SCOPUS:84872236149

VL - 87

SP - 1106

EP - 1117

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 11

ER -